A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

RARECast - Ein Podcast von RARECast - Donnerstags

Kategorien:

Stan Abel, CEO of ProJenX, about ALS, the company’s lead therapeutic candidate prosetin, and the company’s ongoing relationship with Project ALS and Columbia University.

Visit the podcast's native language site